Indian stocks: Visit www.stage2stocks.com →

Ovid Therapeutics Inc.

Stage 3 · Topping · week 1

As of Oct 22, 2026, Ovid Therapeutics is in Stage 3, the topping phase, now in its first week (since Oct 19, 2026). It closed at $2.37, 19.9% below its 52-week high and above its 200-day average, which is rising.

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. More about the company

$2.37
-4.38% today
$463M · Small cap
Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is OVID early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 14w
S4 29w
S2 43w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S3 3w → S2 8w → S3 7w → S4 6w → S1 6w → S4 12w → S1 2w → S4 14w → S1 11w → S4 29w → S1 8w → S2 43w → S3 8w → S2 8w → S3 1w current
Total tracked: 164 weeks across 15 stage runs.

OVID among Biotechnology94th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…94OVIDStage 3 · wk 185−7.8%
vs 52W High
-19.9%
$1.20 lo$2.96 hi
19.9% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 1
1w13w26w
Week 1, early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
1.2%
200 DMA: $2.34 · rising
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.69x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-7.8%
3M
+1.7%
6M
-11.6%
YTD
+34.7%
1Y
+48.1%
Scan Membership
Breakout Watch
Latest: 2023-09-08
5 appearances in last 60 days. First seen: 2019-10-02.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S3
Wk 1 · Vol 0.69x
2026-10-21S3
Wk 1 · Vol 2.83x
2026-10-20S3
Wk 1 · Vol 2.32x
2026-10-19S32→3
Wk 1 · Vol 1.05x
2026-10-16S2
Wk 9 · Vol 0.84x
2026-10-15S2
Wk 8 · Vol 0.84x
2026-10-14S2
Wk 8 · Vol 1.03x
2026-10-13S2
Wk 8 · Vol 1.03x
2026-10-12S2
Wk 8 · Vol 0.55x
2026-10-09S2
Wk 8 · Vol 0.88x
2026-10-08S2
Wk 7 · Vol 1.04x
2026-10-07S2
Wk 7 · Vol 0.63x
Moving averages & range
50 DMA
$2.60
200 DMA
$2.34
52W High
$2.96
52W Low
$1.20
5D Low
$2.15
Resistance levels (recent highs)
20d High
$2.54
60d High
$2.93
120d High
$2.93
250d High
$2.96
Next resistance
+7.2%
to 20d High
ROE
-26.0%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 2.1

Ovid Therapeutics: quick answers

What stage is Ovid Therapeutics in?

As of Oct 22, 2026, Ovid Therapeutics (OVID) is in Stage 3, the topping phase. It entered Stage 3 on Oct 19, 2026 and is in its first week there. What the four stages mean

Is Ovid Therapeutics in an uptrend?

Its uptrend has stalled. Ovid Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 1.2% above its 200-day average, which is rising.

How far is Ovid Therapeutics from its 52-week high?

Ovid Therapeutics closed at $2.37 on Oct 22, 2026, 19.9% below its 52-week high of $2.96. Its 52-week low is $1.20.

How has Ovid Therapeutics performed over the past year?

As of Oct 22, 2026, Ovid Therapeutics is up 48.1% over the past year and up 34.7% so far in 2026.

Which sector and industry is Ovid Therapeutics in?

Ovid Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.